NEW YORK, April 17 – Athersys, which markets its Random Activation of Gene Expression technology for correlation of protein function and gene structure, withdrew its proposed $115 initial public offering in a filing with the Securities and Exchange Commission Tuesday. 

Athersys said it was canceling the IPO due to market conditions. But the Cleveland-based company said it might still sell shares in a private offering.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.